비교리스트

 카트 문의
시장보고서
상품코드
1514009

세계의 단순포진바이러스 감염 시장

Herpes Simplex Virus Infections
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 269 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 단순포진바이러스 감염 시장은 2030년까지 66억 달러에 달할 전망

2023년에 50억 달러로 평가된 세계의 단순포진바이러스 감염 시장은 2023년부터 2030년까지 CAGR 4.0%로 성장할 전망이며, 2030년에는 66억 달러에 달할 것으로 예측됩니다.

미국 시장은 14억 달러, 중국은 CAGR 6.6%로 성장 예측

미국의 단순포진바이러스 감염 시장은 2023년 14억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 14억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 6.6%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.1%와 3.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 2.6%로 성장할 것으로 예측됩니다.

단순포진바이러스 감염-주요 동향 및 촉진요인

단순포진바이러스(HSV) 감염은 두 가지 간단한 헤르페스 바이러스에 의해 유발됩니다. : HSV-1과 HSV-2입니다. HSV-1은 보통 입술 포진을 일으키고, 입술 주변의 냉증과 열성 물집을 보이지만, HSV-2는 주로 생식기 포진을 일으키고 성기와 직장 영역의 누설을 특징으로 합니다. 두 가지 유형의 HSV는 감염성이 강하며 감염자의 피부, 타액 및 생식기 분비액에 직접 접촉하여 감염됩니다. 초기 감염 후, HSV는 신체의 신경 세포에서 휴면 상태에 있으며, 나중에 재활성화되어 재발을 반복 할 수 있습니다. 이러한 재활성화는 스트레스, 질병, 면역 기능 저하 등 다양한 요인에 의해 유발됩니다. HSV 감염은 일반적으로 생명을 위협하지 않지만 재발성이거나 HSV 감염과 관련된 오명으로 인해 심각한 불쾌감과 정신적 고통을 초래할 수 있습니다.

일부 동향과 발전은 HSV 감염의 관리와 치료에 영향을 미칩니다. 한 가지 큰 추세는 아시클로비르, 발라시클로비르, 팜시클로비르와 같은 항바이러스제의 사용이 증가하고 있는데, 이는 중증도 및 발생 빈도를 감소시키는데 도움이 됩니다. 이러한 약물은 발병 시 복용하여 치유를 가속화하고 증상을 가볍게 하거나 억제 요법으로 재발을 예방할 수 있습니다. 또 다른 주목할 만한 연구개발은 HSV 백신의 연구이며, 이는 바이러스에 대한 장기적인 방어를 제공하고 감염률을 감소시키는 것을 목표로 합니다. 또한 진단 기술의 발전으로 HSV 검출의 정확성과 속도가 향상되고 적시에 적절한 치료가 가능합니다. 공중보건 활동은 또한 HSV에 대한 인식을 높이고 감염을 예방하기 위한 안전한 습관을 촉진하고 감염과 관련된 스티그마를 완화하는데 중요한 역할을 합니다.

HSV 감염 치료 시장의 성장은 여러 요인에 의해 견인되고 있습니다. 항바이러스제 제제의 기술적 진보는 치료의 효능과 편의성을 향상시키고, 보다 폭넓은 환자층이 치료에 의해 접근하기 쉬워지고 있습니다. HSV 감염의 세계 유병률 상승은 인지도와 진단률 상승과 함께 효과적인 관리 솔루션에 대한 수요를 확대하고 있습니다. 또한 적극적인 건강관리에 대한 소비자의 동향과 간편한 시판의 치료 옵션에 대한 수요도 시장의 성장에 기여하고 있습니다. 게다가 새로운 치료제와 잠재적인 백신의 발견을 목표로 한 연구개발이 진행되고 있는 것도 큰 성장 기회를 창출할 것으로 기대되고 있습니다. 정부·비정부 조직에 의한 자금 원조나 계발 캠페인도 시장 확대를 더욱 추진하고 있습니다. 이러한 요인을 종합하면 HSV 감염 치료 시장의 견조한 성장이 촉진되고 세계적으로 증가하는 환자의 요구에 대응하고 있습니다.

조사 대상 기업 예(주목의 13사)

  • Admedus Limited
  • Agenus Inc.
  • Aicuris Anti-infective Cures Gmbh
  • Asahi Kasei Corporation
  • Chimerix Inc.
  • Clinigen Group Plc
  • Daewoong Pharmaceutical Co., Ltd.
  • F. Hoffmann-la Roche Ltd.
  • Glaxosmithkline Plc
  • Maruho Co. Ltd.
  • Merck
  • Mylan
  • Novartis
  • Sanofi Pasteur
  • Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global Herpes Simplex Virus Infections Market to Reach US$6.6 Billion by 2030

The global market for Herpes Simplex Virus Infections estimated at US$5.0 Billion in the year 2023, is expected to reach US$6.6 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.6% CAGR

The Herpes Simplex Virus Infections market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Herpes Simplex Virus Infections - Key Trends and Drivers

Herpes Simplex Virus (HSV) infections are caused by two types of herpes simplex viruses: HSV-1 and HSV-2. HSV-1 typically causes oral herpes, which presents as cold sores or fever blisters around the mouth, while HSV-2 primarily causes genital herpes, characterized by sores in the genital or rectal area. Both types of HSV are highly contagious and can be transmitted through direct contact with an infected person’s skin, saliva, or genital secretions. After the initial infection, HSV can remain dormant in the body’s nerve cells and reactivate later, leading to recurrent outbreaks. These reactivations can be triggered by various factors such as stress, illness, or weakened immune function. While HSV infections are generally not life-threatening, they can cause significant discomfort and emotional distress due to their recurrent nature and the stigma associated with them.

Several trends and developments are influencing the management and treatment of HSV infections. One major trend is the increasing use of antiviral medications such as acyclovir, valacyclovir, and famciclovir, which can help reduce the severity and frequency of outbreaks. These medications can be taken during outbreaks to accelerate healing and lessen symptoms or as suppressive therapy to prevent recurrent episodes. Another notable development is the research into HSV vaccines, which aim to provide long-term protection against the virus and reduce transmission rates. Additionally, advancements in diagnostic technologies are improving the accuracy and speed of HSV detection, enabling timely and appropriate treatment. Public health initiatives are also playing a crucial role in raising awareness about HSV, promoting safe practices to prevent transmission, and reducing the stigma associated with the infection.

The growth in the HSV infections treatment market is driven by several factors. Technological advancements in antiviral drug formulations are enhancing the effectiveness and convenience of treatments, making them more accessible to a broader patient population. The rising prevalence of HSV infections worldwide, coupled with increasing awareness and diagnosis rates, is expanding the demand for effective management solutions. Consumer behavior trends towards proactive health management and the demand for convenient, over-the-counter treatment options are also contributing to market growth. Furthermore, ongoing research and development activities aimed at discovering new therapeutic agents and potential vaccines are expected to generate significant growth opportunities. The support from governmental and non-governmental organizations in terms of funding and awareness campaigns is further propelling market expansion. Collectively, these factors are driving robust growth in the HSV infections treatment market, addressing the needs of an increasing number of affected individuals globally.

Select Competitors (Total 13 Featured) -

  • Admedus Limited
  • Agenus Inc.
  • Aicuris Anti-infective Cures Gmbh
  • Asahi Kasei Corporation
  • Chimerix Inc.
  • Clinigen Group Plc
  • Daewoong Pharmaceutical Co., Ltd.
  • F. Hoffmann-la Roche Ltd.
  • Glaxosmithkline Plc
  • Maruho Co. Ltd.
  • Merck
  • Mylan
  • Novartis
  • Sanofi Pasteur
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Herpes Simplex Virus Infections - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Use of Antiviral Medications Propels Growth in HSV Treatment Market
    • Advancements in Diagnostic Technologies Strengthen Business Case for Early Detection
    • Research into HSV Vaccines Expands Addressable Market Opportunity
    • Public Health Initiatives and Awareness Campaigns Drive Adoption of Preventive Measures
    • Rising Prevalence of HSV Infections Spurs Demand for Effective Management Solutions
    • Advancements in Antiviral Drug Formulations Generate Demand for Improved Treatments
    • Increasing Over-the-Counter Treatment Options Expand Market Reach
    • Innovations in Suppressive Therapy Techniques Sustain Growth in HSV Treatment Market
    • Development of Long-Term Protective Vaccines Bodes Well for the Market
    • Advances in Genetic and Molecular Research Expand Opportunities for Novel HSV Treatments
    • Increasing Incidence of Stress and Immunocompromised Conditions Spurs Demand for HSV Management
    • Personalized Medicine and Tailored Therapies Drive Adoption of Customized HSV Treatment Plans
    • Digital Health Solutions and Telemedicine Enhance Access to HSV Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Herpes Simplex Virus Infections Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Herpes Simplex Virus Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Herpes Simplex Virus Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Herpes Simplex Virus Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Herpes Simplex Virus Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Herpes Simplex Virus Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Herpes Simplex Virus Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Herpes Simplex Virus Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Herpes Simplex Virus Infections by Segment - Herpes Simplex Virus Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제